1. Medtech Insight
  2. >>Business
  3. >>Deals

Nestlé's Microbiome Interest Deepens With Enterome JV

 
• By Catherine Longworth

Nestlé Health Science has invested $23m in a joint venture it is setting up with French microbiome company Enterome. Microbiome Diagnostics Partners (MDP) will be focused on developing microbiome-based diagnostics for the assessment and management of irritable bowel disorder and liver diseases.

Handshake of businessmen

French microbiome company Enterome is teaming up with Swiss nutritionals giant Nestlé Health Science to form a joint venture focused on developing microbiome-based diagnostics. Nestlé will invest €20m ($23m) in return for a 50% stake in Microbiome Diagnostics Partners (MDP). In addition, it will make further payments to MDP if it achieves certain clinical and commercial milestones. Enterome will contribute to the JV its current microbiome diagnostic programs and intellectual property derived from its microbiome-based platforms.

The main focus of the joint venture will be to accelerate commercialization of Enterome's diagnostic platforms which include IBD110, a biomarker for patients with Crohn's disease or inflammatory bowel disease...

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.